成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Cell Cycle/DNA Damage Stem Cell/Wnt Autophagy Apoptosis
  3. CDK Wnt Autophagy Apoptosis
  4. Wogonin

Wogonin 是一種天然黃酮類物質(zhì)，能夠抑制 CDK8 和 Wnt 的活性，具有抗炎、抗腫瘤等功效。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Wogonin Chemical Structure

Wogonin Chemical Structure

CAS No. : 632-85-9

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥500
In-stock
5 mg ￥450
In-stock
10 mg ￥750
In-stock
50 mg ￥3000
In-stock
100 mg   詢價(jià)  
200 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Wogonin:

    Wogonin purchased from MCE. Usage Cited in: J Immunol Res. 2020 Jun 1;2020:3032425.  [Abstract]

    Dose-dependent inhibition of STAT3 and ERK phosphorylation by Wogonin in LPS-treated B cells. CD19+ B cells were cultured with LPS for 6?h in the presence or absence of Wogonin (12.5, 25, and 50?μM) are analyzed and quantified by Western Blot.

    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

    IC50 & Target[1]

    CDK8

     

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    15.8 μM
    Compound: 1
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28117202]
    A549 IC50
    20.1 μM
    Compound: 1
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28987604]
    A549 IC50
    42.3 μM
    Compound: Wogonin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31238183]
    B16 IC50
    26.4 μM
    Compound: 1
    Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28987604]
    BV-2 IC50
    7.8 μM
    Compound: Wgn, Wogonin
    Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs
    Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs
    		[PMID: 22366656]
    DLD-1 IC50
    36.87 μM
    Compound: 3; Wogonin
    Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay
    		10.1039/C5MD00163C
    HCT-116 IC50
    27.3 μM
    Compound: Wogonin
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31238183]
    HepG2 IC50
    17.6 μM
    Compound: Wogonin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31238183]
    HepG2 IC50
    19 μM
    Compound: 1
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28117202]
    HepG2 IC50
    19.5 μM
    Compound: 1
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28987604]
    HepG2 IC50
    37.89 μM
    Compound: 3; Wogonin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		10.1039/C5MD00163C
    HepG2 2.2.15 IC50
    4 μg/mL
    Compound: 1
    Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days
    Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days
    		[PMID: 24549242]
    HT-29 IC50
    39.55 μM
    Compound: 3; Wogonin
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    		10.1039/C5MD00163C
    HUVEC IC50
    105 μM
    Compound: 3
    Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA
    Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA
    		[PMID: 9214730]
    MCF7 IC50
    28 μM
    Compound: 1
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28987604]
    MCF7 IC50
    30 nM
    Compound: 44
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 36205223]
    MCF7 IC50
    30 μM
    Compound: Wagonin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32707525]
    MCF7 IC50
    30 μM
    Compound: Wogonin
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 31300317]
    MV4-11 IC50
    30.7 μM
    Compound: Wogonin
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31238183]
    RAW264.7 IC50
    1.07 μM
    Compound: Wogonin
    Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay
    Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay
    		[PMID: 19233646]
    Sf21 IC50
    12.3 μM
    Compound: 22
    Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis
    Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis
    		[PMID: 30733087]
    Sf9 IC50
    190 nM
    Compound: Wogonin
    Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b
    Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b
    		[PMID: 31238183]
    Sf9 IC50
    190 nM
    Compound: 22
    Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy
    Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy
    		[PMID: 30733087]
    SW480 IC50
    35.06 μM
    Compound: 3; Wogonin
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    		10.1039/C5MD00163C
    體外研究
    (In Vitro)

    Wogonin (0-200 μM) exhibits a dose- and time- dependent reduces in cell viability of caco-2, SW1116 and HCT116 cells. Wogonin (10-40 μM) induces G1 phase arrest in HCT-116 cells. Wogonin also supresses Wnt signaling pathway in HCT116 cells. Wogonin interfers in the activity of transcription factor TCF/Lef family. Moreover, Wogonin inhibits β-catenin-mediated transcription through suppressing the activity of CDK8[1]. Wogonin shows cytotoxic and antiproliferative effects on HeLa cells. Wogonin (90 μM) induces cell cycle arrest at G0-G1 phase, and suppresses the levels of cyclin D1 and Cdk4 markedly in HeLa cells[2]. Wogonin (1.25, 2.5, 5, 10, 20 μg/ml) suppresses EtOH-induced inflammatory response in RAW264.7 cells[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    Wogonin (30, 60 mg/kg) reduces tumor growth of HCT116 cells in a xenograft model[1]. Wogonin (25, 50, 100 mg/kg) protects against liver injury and pathological characteristics of ALD in mice. Wogonin activates PPAR-γ expression in mice with ALD and EtOH induced RAW264.7 cells[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    284.26

    Formula

    C16H12O5
    CAS 號
    性狀

    固體

    顏色

    Light yellow to yellow

    中文名稱

    漢黃芩素；漢黃芩黃酮
    結(jié)構(gòu)分類
    初始來源
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 62.5 mg/mL (219.87 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.5179 mL 17.5895 mL 35.1791 mL
    5 mM 0.7036 mL 3.5179 mL 7.0358 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲存時，請?jiān)?個月內(nèi)使用，-20°C儲存時，請?jiān)?個月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實(shí)驗(yàn)：

    請根據(jù)您的 實(shí)驗(yàn)動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.08 mg/mL (7.32 mM); 懸濁液; 超聲助溶

      此方案可獲得 2.08 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 0.5% CMC-Na/saline water

      Solubility: 24 mg/mL (84.43 mM); 懸濁液; 超聲助溶

    動物溶解方案計(jì)算器
    請輸入動物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實(shí)驗(yàn)過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.92%

    參考文獻(xiàn)
    Cell Assay
    [1]

    HCT116 cells are planted on a 96-well plate (1 × 105 cells per well). Different concentrations of wogonin are added and incubated for 24 h. Subsequently, 20 μL of MTT solution (5 mg/mL) is transferred to each well and the plates are incubated for 4 h at 37°C and 5% CO2. The supernatant is aspirated off and 100 μL DMSO is added to dissolve the formazan crystal. The mixture is shaken and measured at 570 nm using a universal microplate reader.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [3]

    C57BL/6 mice, male, 6-8 weeks old, weighing 18-22 g mice are housed at comfortable environment and are acclimatized for 3 days before the experiment. A total of 48 mice are randomLy divided into six groups of 8 animals, respectively control diet (CD)-fed mice, EtOH-fed mice, wogonin-treated mice at the dose of 25, 50, 100 mg/kg/day and the positive (dexamethasone, 1 mg/kg/day)-treated mice. Modeling process has a total of 16 days including a liquid diet adaptation period for 3 days and modeling for 13 days. The EtOH-fed mice are fed containing 5% v/v ethanol liquid diets adding certain vitamin and choline for 16 days, and mice are gavaged with a single binge ethanol administration (5 g/kg, body weight, 20% ethanol) at last day. At the same time, the wogonin-treated mice and the positive-treated mice are not only plus the ethanol administration, but also plus the medicines by gavage daily, whereas the CD-fed mice are fed with control liquid diets and gavaged with isocaloric maltose-dextrin at last day. All diets are prepared fresh daily. 9 h after the last gavage alcohol, mice are sacrificed under anaesthesia, the liver tissues and blood are collected for further analysis.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲存時，請?jiān)?個月內(nèi)使用，-20°C儲存時，請?jiān)?個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5179 mL 17.5895 mL 35.1791 mL 87.9477 mL
    5 mM 0.7036 mL 3.5179 mL 7.0358 mL 17.5895 mL
    10 mM 0.3518 mL 1.7590 mL 3.5179 mL 8.7948 mL
    15 mM 0.2345 mL 1.1726 mL 2.3453 mL 5.8632 mL
    20 mM 0.1759 mL 0.8795 mL 1.7590 mL 4.3974 mL
    25 mM 0.1407 mL 0.7036 mL 1.4072 mL 3.5179 mL
    30 mM 0.1173 mL 0.5863 mL 1.1726 mL 2.9316 mL
    40 mM 0.0879 mL 0.4397 mL 0.8795 mL 2.1987 mL
    50 mM 0.0704 mL 0.3518 mL 0.7036 mL 1.7590 mL
    60 mM 0.0586 mL 0.2932 mL 0.5863 mL 1.4658 mL
    80 mM 0.0440 mL 0.2199 mL 0.4397 mL 1.0993 mL
    100 mM 0.0352 mL 0.1759 mL 0.3518 mL 0.8795 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Wogonin
    目錄號：
    HY-N0400
    需求量：